Tech Session VII: Nanomedicine and Nanoscale Delivery (Focus: Bioengineering)
Lipid Nanoparticles Comprising Poly-phosphocholine Conjugates for Nucleic Acid Delivery
Friday, July 18, 2025
9:05 AM - 9:16 AM EDT
Location: 121 B/C
Introduction: The recent success of RNA-based strategies emerges from the ability of lipid nanoparticles (LNPs) to overcome delivery challenges post-administration. All FDA-approved LNPs to date are functionalized with poly(ethylene glycol) (PEG); however, they face challenges, including immunogenic responses, compromising clinical outcomes and safety. Zwitterionic poly[2-(methacryloyloxy)ethyl phosphorylcholine] (pMPC), a methacrylate with a highly hydrated phosphorylcholine group resembling the headgroup of naturally occurring phosphatidylcholine lipids, could be used as a safe alternative to PEG.
Learning Objectives:
At the completion of this activity, participants will know
Developing novel LNPs for the delivery of mRNA as alternatives of the gold-standard PEG.
Understanding how the different molecular weight of pMPC affects the performance of the LNPs.
Evaluating the PEGylated and pMPCylated-LNPs structure through Cryo-TEM and AFM.
Lin Weifeng, Beihang University, China – Professor, Beihang University, China; Monika Kluzek, IMol Polish Academy of Sciences, Warsaw, Poland – Group Leader, IMol Polish Academy of Sciences, Warsaw, Poland; Roman Kamyshinsky, Weizmann Institute of Science, Rehovot, Israel – Staff Scientist, Weizmann Institute of Science, Rehovot, Israel; Nir Kampf, Weizmann Institute of Science, Rehovot, Israel – Staff Scientist, Weizmann Institute of Science, Rehovot, Israel; Jacob Klein, Weizmann Institute of Science, Rehovot, Israel – Professor, Weizmann Institute of Science, Rehovot, Israel
